MMP-13 antagonist
BI-4394
BI-4394 is a highly potent inhibitor of matrix metalloproteinase MMP-13 (IC50 = 1 nM) with excellent selectivity (> 1,000-fold) against several other matrix metalloproteinases. This compound is a high-quality tool to test, in vitro, biological hypothesis involving this target.
According to the UK Third Generation Cannabinoid Act, the molecule cannot be shipped to the United Kingdom.
More information
Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent peptidases, involved in the cleavage of collagen, gelatin and other proteins in the extracellular matrix and tissue remodelling. There are approximately 23 known human MMPs that are grouped into subtypes based on their substrates. MMPs have a conserved active site motif where a tris(histidine)-bound zinc (II) acts as the catalytic site for substrate hydrolysis. MMP-13 (also known as collagenase 3, CLG3) is the most efficient enzyme of this class at degrading collagen II, the committed step in articular cartilage degradation and progressive joint damage associated with rheumatoid arthritis (RA). Broad-spectrum MMP inhibitors have failed in clinical trials at least in part due to a joint-stiffening side effect, termed musculoskeletal syndrome (MSS). This was likely due to inhibition of MMPs other than MMP-13 and high selectivity for MMP-13 over other MMPs is therefore favourable.
BI-4394 bound to MMP-13, as observed by X-ray crystallography (PDB code: 5BPA)
BI-4394 is a potent inhibitor of MMP-13 with an IC50 value of 1 nM.
| Probe name / negative control | BI-4394 | BI-4395 |
| MW [Da, free base]a | 446.5 | 374.4 |
| Inhibition of MMP-13 (IC50) [nM] | 1 | >26,000 |
| Inhibition of bovine nasal cartilage with human full length MMP-13 (IC50) [nM] | 31 | n.d. |
a For the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs
| Probe name / negative control | BI-4394 | BI-4395 | ||
| logP @ pH 2 | 1.9 | n.d. | ||
| Solubility @ pH 7.4 [µg/mL] | 60 | >96 (pH 7) | ||
| Solubility @ pH 4 [µg/mL] | <0.1 | <0.1 | ||
| Caco-2 permeability AB @ pH 7.4 [*10-6 cm/s] | 0.6 | n.d. | ||
| Caco-2 efflux ratio | 27 | n.d. | ||
| Microsomal stability (human/rat) [% QH] | 40 / 41 | 25 / n.d. | ||
| Plasma protein binding (human) [%] | 98 | n.d. | ||
| BI-4394 | RAT |
| Clearance [ml/(min*kg)]a | 39 |
| Mean residence time after i.v. dose [h] | 0.5 |
| Vss [l/kg] | 0.4 |
a i.v. dose: 1 mg/kg
BI-4395 which serves as a negative control
BI-4394 is highly (> 1000 fold) selective against other matrix metalloproteinases (MMP-1, 2, 3, 7, 8, 9, 10, 12, 14):
MMP | 1 | 2 | 3 | 7 | 8 | 9 | 10 | 12 | 13 | 14 |
IC50 [µM] | >22 | 18 | >22 | >22 | >22 | 8.9 | 16 | >22 | 0.001 | 8.3 |
| SELECTIVITY DATA AVILABLE | BI-4394 | BI-4395 |
SafetyScreen44™ with kind support of  | Yes | Yes |
| PDSP6 | Yes | Yes |
| Invitrogen® | Yes | No |
| DiscoverX® | No | No |
| Dundee | No | No |
Invitrogen:
18/56 kinases hit >50 inhibition at 10 µM: STK6 (99%), MAPKAPK2 (99%), RPS6KA3 (95%), MAPK14 (94%), GSK3B (94%), AMPK A1B1G1 (92%), PRKACA (90%), PIM1 (86%), KDR (83%), AKT1 (76%), SRC (75%), DYRK3 (72%), MAP4K4 (68%), MET (57%), JAK3 (56%), IKBKB (52%), ABL1 (52%), NEK1 (51%).
Download selectivity data:
BI-4394_selectivityData.xlsx
BI-4395_selectivityData.xlsx
X-Ray co-crystal structure of BI-4394 bound to MMP-13 is available (see Figure "BI-4394 bound to MMP-13, as observed by X-ray crystallography (PDB code: 5BPA)", PDB code: 5BPA).
BI-4394 is a potent and highly selective inhibitor of MMP-13 that can be used as tool compound to test biological hypotheses in vitro.
According to the UK Third Generation Cannabinoid Act, the molecule cannot be shipped to the United Kingdom.
Fragment-Based Discovery of Indole Inhibitors of Matrix Metalloproteinase-13
Taylor S. J., Abeywardane A., Liang S., Muegge I., Padyana A. K., Xiong Z., Hill-Drzewi M., Farmer B., Li X., Collins B., Li J. X., Heim-Riether A., Proudfoot J., Zhang Q., Goldberg D., Zuvela-Jelaska L., Zaher H., Li J., Farrow N. A.
J. Med. Chem. 2011, 54, 8174.
Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors
Heim-Riether A, Taylor S. J., Liang S., Gao D. A., Xiong Z., Michael August E., Collins B. K., Farmer B. T. 2nd, Haverty K., Hill-Drzewi M., Junker H. D., Mariana Margarit S., Moss N., Neumann T., Proudfoot J. R., Keenan L. S., Sekul R., Zhang Q., Li J., Farrow N. A.
Bioorg. Med. Chem. Lett. 2009, 19, 5321.
SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability
Gao D.A., Xiong Z., Heim-Riether A., Amodeo L., August E. M., Cao X., Ciccarelli L., Collins B. K., Harrington K., Haverty K., Hill-Drzewi M., Li X., Liang S., Margarit S.M., Moss N., Nagaraja N., Proudfoot J., Roman R., Schlyer S., Keenan L.S., Taylor S., Wellenzohn B., Wiedenmayer D., Li J., Farrow N. A.
Bioorg. Med. Chem. Lett. 2010, 20, 5039.
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)- 5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Trea
Ruminski P. G., Massa M., Strohbach J., Hanau C. E., Schmidt M., Scholten J. A., Fletcher T. R., Hamper B. C., Carroll J. N., Shieh H. S., Caspers N., Collins B., Grapperhaus M., Palmquist K. E., Collins J., Baldus J. E., Hitchcock J., Kleine H. P., Rogers M. D., McDonald J., Munie G. E., Messing D. M., Portolan S., Whiteley L. O., Sunyer T., Schnute M. E.
J. Med. Chem. 2016, 59, 313.
When you plan a publication, please use the following acknowledgement:
BI-4394 was kindly provided by Boehringer Ingelheim via its open innovation platform opnMe, available at https://www.opnme.com.